Arcutis Joins with Habitat for Humanity of Ventura County to Construct and Decorate Playhouses for Military and Veteran Families
● Arcutis team members will build 15 playhouses for donation to children of military and veteran families
WESTLAKE VILLAGE, Calif., July 8, 2021 -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a biopharmaceutical company dedicated to revolutionizing the treatment of serious skin diseases, has partnered with Habitat for Humanity of Ventura County for a playhouse build outside of the Arcutis headquarters in Westlake Village. Over 100 Arcutis team members will construct and decorate 15 children’s playhouses, which will then be donated to military and veteran families.
In addition, Arcutis is providing a donation to help fund the construction of Habitat homes for struggling families in Ventura County.
“We’re proud to partner with Habitat for Humanity of Ventura County to help give back to the community we call home. And as a former commissioned officer in the U.S. Navy Reserves, it is also rewarding to have the opportunity to directly support our military and veteran families,” said Frank Watanabe , President and Chief Executive Officer, Arcutis. “Our team is looking forward to working together on this purposeful project and be reminded of the importance of spreading joy where we can.”
The playhouse build will take place on Wednesday, July 14, from 8 a.m. to 2 p.m. PDT.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with seven clinical programs for a range of inflammatory dermatological conditions, with our first NDA submission anticipated by the end of 2021 and three more Phase 3 clinical data readouts anticipated over the next 18 months. The company’s lead product candidate, topical roflumilast, has the potential to advance the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn and Twitter.
This press release contains "forward-looking" statements, including, among others, statements regarding the potential for roflumilast to revolutionize the standard of care in plaque psoriasis and other inflammatory dermatological conditions. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the "Risk Factors" section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 16, 2021, as well as any subsequent filings with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Investor and Media Contact: